SG Americas Securities LLC Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

SG Americas Securities LLC bought a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 4th quarter, HoldingsChannel.com reports. The firm bought 6,308 shares of the company’s stock, valued at approximately $108,000.

Several other large investors have also modified their holdings of NMRA. Legal & General Group Plc purchased a new position in Neumora Therapeutics during the 3rd quarter worth approximately $140,000. Soros Fund Management LLC acquired a new stake in shares of Neumora Therapeutics in the third quarter valued at approximately $141,000. Citigroup Inc. acquired a new stake in shares of Neumora Therapeutics in the third quarter valued at approximately $203,000. Royal Bank of Canada purchased a new position in shares of Neumora Therapeutics during the third quarter worth approximately $283,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Neumora Therapeutics in the 3rd quarter valued at $302,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a research report on Friday, April 12th. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of Neumora Therapeutics in a report on Thursday, March 28th. Finally, JPMorgan Chase & Co. boosted their price target on Neumora Therapeutics from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.57.

Neumora Therapeutics Stock Performance

NMRA stock opened at $10.18 on Friday. The company has a fifty day moving average of $15.52 and a 200-day moving average of $14.14. Neumora Therapeutics, Inc. has a one year low of $9.35 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.05. As a group, equities analysts anticipate that Neumora Therapeutics, Inc. will post -1.48 earnings per share for the current fiscal year.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.